The late-stage head-to-head trial compared different doses of the two drugs in patients with diabetes and obesity to assess glycemic control and weight loss. One group received a 6 mg dose of the mazdutide drug that Innovent develops and the other a 1 mg dose of injectable semaglutide.
Sign up here.
Novo sells injectable semaglutide for patients with type 2 diabetes in China under the brand name Ozempic to control blood sugar.
In the trial, which enrolled 349 adults with type 2 diabetes and obesity, mazdutide showed greater improvements in both HbA1C – a measure of blood sugar over time – and weight reduction.
Patients who took Innovent’s drug at the 6 mg dose lost a mean of 10.29% of their weight from baseline compared to 6% with the 1 mg dose of injectable semaglutide. Innovent’s drug also lowered patients’ HbA1C by a mean of 2.03, compared to 1.84 for the 1 mg dose of injectable semaglutide.
“The head-to-head DREAMS-3 study comparing mazdutide with semaglutide further showed that in patients with T2D and comorbid obesity mazdutide provides superior efficacy in both weight loss and glucose lowering,” Innovent’s chief R&D officer of general biomedicine, Lei Qian, said in a statement.
A Novo Nordisk spokesperson did not immediately respond to a request for comment sent outside of normal business hours.
Reporting by Andrew Silver in Shanghai; Editing by Muralikumar Anantharaman
Our Standards: The Thomson Reuters Trust Principles.
